No abstract

Thrombocyte glycoprotein IIb/IIIa inhibitors prevent fibrinogen binding and thereby thrombocyte aggregation. The inhibition of thrombocyte activation at the damaged coronary plaque is the target of the new therapeutic strategies in treating acute coronary syndrome. This reduces the ischemic complications associated with the non-STelevation myocardial infarction (NSTEMI) and percutaneous coronary intervention (PCI). Thrombocytopenia is a known complication of glycoprotein (GP) IIb/IIIa inhibitors. Although, in general, GP IIb/IIIa inhibitor-induced thrombocytopenia is a harmless side effect which responds readily to thrombocyte transfusion, it can occasionally be a very serious complication associated with serious bleeding. In addition patients developing thrombocytopenia have unfavorable outcome (e.g., death, myocardial infarction, bypass surgery or additional PCI) in comparison to patients without thrombocytopenia. Advanced age (> 65 years), low BMI and a low initial thrombocyte count (<180,000/microl) are independent risk factors of thrombocytopenia. The risk of bleeding is higher with this form of thrombocytopenia not only due to the low thrombocyte count but also to the impaired function of the remaining thrombocytes. It is important to closely monitor platelet count during GP IIb/IIIa antagonist treatment. Platelet count monitoring two, six, twelve and 24 hour after starting the treatment reveals most cases of acute thrombocytopenia. Side effects can be avoided by the early discontinuation of the GP IIb/IIIa antagonist treatment. This article reviews the diagnosis and treatment of glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia and summarizes the differential diagnosis from heparin-induced thrombocytopenia and laboratory-related pseudothrombocytopenia.

No abstract

A novel hydrocarbon-degrading, Gram-negative, obligately aerobic, non-motile, non-sporulating, rod-shaped bacterium, designated strain TBF2/20.2 T , was isolated from a biofilter clean-up facility set up on a hydrocarbon-contaminated site in Hungary. It was characterized by using a polyphasic approach to determine its taxonomic position. Phylogenetic analysis based on 16S rRNA gene sequences indicated that the isolate is affiliated with the genus Olivibacter in the family Sphingobacteriaceae. It was found to be related most closely to Olivibacter ginsengisoli Gsoil 060 T (93.3 % 16S rRNA gene sequence similarity). Strain TBF2/20.2 T grew at pH 6-9 (optimally at pH 6.5-7.0) and at 15-42 6C (optimally at 30-37 6C). The major fatty acids were iso-C 15 : 0 (39.4 %), summed feature 3 (iso-C 15 : 0 2-OH and/or C 16 : 1 v7c; 26.0 %), iso-C 17 : 0 3-OH (14.5 %) and C 16 : 0 (4.5 %). The major menaquinone was MK-7 and the predominant polar lipid was phosphatidylethanolamine. The DNA G+C content of strain TBF2/20.2 T was 41.2 mol%. Physiological and chemotaxonomic data further confirmed the distinctiveness of strain TBF2/20.2 T from recognized members of the genus Olivibacter. Thus, strain TBF2/20.2 T is considered to represent a novel species of the genus Olivibacter, for which the name Olivibacter oleidegradans sp. nov. is proposed. The type strain is TBF2/20.2 T (5NCAIM B 02393 T 5CCM 7765 T ).The genus Olivibacter, family Sphingobacteriaceae (Euzéby, 1997), was proposed by Ntougias et al. (2007) and, at the time of writing, comprised four recognized species: Olivibacter sitiensis, isolated from alkaline olive-oil mill wastes (Ntougias et al., 2007), and Olivibacter ginsengisoli, Olivibacter terrae and Olivibacter soli (Wang et al., 2008), isolated from soil of a ginseng field and compost in South Korea. The present study describes the taxonomic characterization of a novel Olivibacter-like bacterial strain, designated TBF2/20.2 T .Strain TBF2/20.2 T was isolated from a clean-up facility at a volatile hydrocarbon-contaminated site in Hungary. A biofilter was used for bioremediation of contaminated groundwater by using ex situ, on-site treatment. A sample was taken from the biofilter and 10 g of the sample was stirred thoroughly for 20 min in 90 ml physiological saline (0.9 %, w/v, NaCl) solution and glass beads. Serial dilutions were made and plated on TGY5 agar plates [per litre distilled water: 5 g tryptone, 2.5 g yeast extract, 5 g glucose (all from BioLab Inc.) and 15 g agar agar (Merck)] and incubated at 30 u C for 72 h. Colonies were selected randomly and subsequently purified twice on TGY5 agar medium at 30 u C.Hydrocarbon degradation was tested on prediluted and sterilized diesel oil solution prepared by a Hungarian accredited analytical laboratory (Wessling Hungary Ltd). To confirm oil degradation, 450 ml of this solution was inoculated with strain TBF2/20.2 T growing in 50 ml TGY5 broth (final volume 500 ml) and incubated for 5 days in a rotary shaker (120 r.p.m.) at 25 u C. Uninoculated solution with the addi...

No abstract